Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S, Willison A, Korsen M, Kölsche T, Golombeck KS, Plaack B, Schüller J, Huntemann N, Rolfes L, Schroeter CB, Nelke C, Regner-Nelke L, Förster M, Ringelstein M, Barnett MH, Hartung HP, Aktas O, Albrecht P, Ruck T, Melzer N, Meuth SG, Kremer D.
Räuber S, et al. Among authors: hartung hp.
Front Immunol. 2022 Dec 23;13:1037214. doi: 10.3389/fimmu.2022.1037214. eCollection 2022.
Front Immunol. 2022.
PMID: 36618356
Free PMC article.